|Day Low/High||9.92 / 10.35|
|52 Wk Low/High||7.26 / 19.90|
The most recent short interest data was recently released for the 02/28/2019 settlement date, and Iovance Biotherapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 11.19 "days to cover" versus the median component at 4.57. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.
Investors in Iovance Biotherapeutics Inc saw new options begin trading this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IOVA options chain for the new February 15th contracts and identified the following call contract of particular interest.
Shares of Iovance Biotherapeutics and Reata Pharmaceuticals took it on the chin in the fourth quarter, but both companies seem ready to reward shareholders for their patience.
Quotient Limited, Iovance Biotherapeutics and AVEO Pharmaceuticals are among the names seeing insider purchases.
You don't have to be Sigmund Freud to understand the psychology here.
Jim Cramer takes a closer look at Magellan Midstream Partners, Xylem, Boston Scientific, Karyopharm Thereapeutics, Iovance Biotherapeutics, Casella Waste Systems and more.
Jim Cramer says higher rates always trigger rotations. Here's what investors should expect.
Investors in Iovance Biotherapeutics Inc saw new options begin trading this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IOVA options chain for the new July 20th contracts and identified the following call contract of particular interest.
While I'm waiting for some index excitement I'm focused on trades in individual stocks.
These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.
Company to Host Conference Call at 4:30pm ET Today
Industry Veteran Brings Significant Clinical, Commercial, and Business Experience
Former Attorney General of Louisiana, Charles C. Foti, Jr.
The market's reaction to James Bullard's comments this morning is following an all-too-common pattern.
Here's what you need to know now for Wednesday, Feb. 14.
It's hard to believe the bounce will continue to run in V-shaped fashion.
If we have a little consolidating action here the buyers will start pushing again.
These five 'Strong Buy' stocks boast a double whammy of only buy ratings and big upside potential. After the market's recent plunge, this list is quite handy.
In addition to the State of the Union address and the Fed interest rate decision, companies representing about 25% of the Nasdaq 100's market cap will report results in the next two days.
While painful to longs, the market will be better for it.
It would be a longer-term positive if the overbought conditions are alleviated.
The challenge of this market is to keep finding new buy entries as more and more stocks become extended.
Only when the picking worsens will I start to worry.
The sector has been a great trading group lately and I bought these 2 names this morning.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.